Research programme: immunosuppressive therapeutics - Abbott Laboratories
Alternative Names: A 420983; A-770041; Immunosuppressive therapeutics research programme - Abbott Laboratories; Lck inhibitors - Abbott LaboratoriesLatest Information Update: 24 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 24 Jan 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 19 May 2004 Data presented at the American Transplant Congress 2004 (ATC-2004) have been added to the Transplant rejection pharmacodynamics section
- 16 Sep 2002 Preclinical trials in Transplant rejection in USA (unspecified route)